UNSPSC 51162643: Nicocodine

This classification denotes an antitussive agent with the molecular formula C24H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) DYX391P13E, chemically known as morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, 3-pyridinecarboxylate (ester), (5.alpha.,6.alpha.)- but more generally known as nicocodine, which bears US NIH Compound Identifier 520825. European Medicines Agency schedules Nicocodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09233MIG.

UNSPSC 51162643 Nicocodine is a Commodity code that in practice covers the procurement of naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products by state and local government health and public-safety agencies. State and local governments buying under this code are securing emergency-response medications, harm-reduction supplies, and bulk pharmaceutical inventories for community health facilities, emergency services, and healthcare delivery networks. The issuing bodies include county health departments, state purchasing alliances, and cooperative purchasing organizations spanning multiple jurisdictions. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represent the primary recent activity.

Recent opportunities show geographically dispersed procurement concentrated in Florida and Minnesota, with MMCAP's scope extending to participating state and local facilities in Oregon and across the multistate cooperative. Seminole County issued an Invitation for Bid (IFB 60459723LAS, posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract included a two-year initial term with one-year renewal option and required E-Verify compliance, drug-free workplace certification, and potential FEMA funding with federal regulatory compliance. The Minnesota Department of Administration issued an RFP (S1070000015802, posted January 20, 2026, due March 26, 2026) through MMCAP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), provide detailed National Drug Code information, certify cGMP and Drug Supply Chain Security Act compliance, and maintain specific insurance thresholds; evaluation weighted price competitiveness at 75 percent, with contract effectiveness set for July 1, 2026.